Cart is empty More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumor cells, with less need for chemotherapy, following results of multiple clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023.
Leave A Comment